Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 28Head & Neck 14Gastrointestinal 13CNS 13Genitourinary 10Breast 9Endocrine 7Tumor-Agnostic 6Sarcoma 5Other solid neoplasm 3Gynecologic 3Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Dermatologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
vandetanib × Gynecologic × Clear all
NCT00872989 2016-12-19

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

SWOG Cancer Research Network

Phase 2 Completed
129 enrolled 17 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00862836 2016-10-10

ZACFAST

Sanofi

Phase 1/2 Terminated
15 enrolled 13 charts
Gynecologic

Ovarian Neoplasms

NCT00445549 2012-06-26

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
12 enrolled 5 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡